Expert review of vaccinesHumansRespiratory Syncytial Virus InfectionsInfantUnited StatesRespiratory Syncytial Virus Vaccines
Comparison of the public health impact of RSV disease prevention options for infants: a static decision model of the US birth cohort.
Alexia Kieffer, Mehdi Ghemmouri, Samira Soudani, Thomas Shin, Erin Hodges, Michael Greenberg, Maribel Tribaldos, Ayman Chit, Matthieu Beuvelet, Maureen P Neary, Veronica Gabriel, Leonard R Krilov, Jeroen Geurtsen, Robert Musci, Benjamin Yarnoff
Published: 202510.1080/14760584.2025.2591816
Abstract
BACKGROUND: In the U.S.A. three prophylactic interventions are approved for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in infants: nirsevimab and clesrovimab (extended half-life monoclonal antibodies) a…
Preview only. Read the full abstract at the source